Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Immunogenic and Non-immunogenic Cell Death in the Tumor Microenvironment.

Pitt JM, Kroemer G, Zitvogel L.

Adv Exp Med Biol. 2017;1036:65-79. doi: 10.1007/978-3-319-67577-0_5. Review.

PMID:
29275465
2.

The renaissance of anti-neoplastic immunity from tumor cell demise.

Ma Y, Pitt JM, Li Q, Yang H.

Immunol Rev. 2017 Nov;280(1):194-206. doi: 10.1111/imr.12586. Review.

PMID:
29027231
3.

Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance.

Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, Yamazaki T, Bonneil E, Buqué A, Humeau J, Drijfhout JW, Meurice G, Walter S, Fritsche J, Weinschenk T, Rammensee HG, Melief C, Thibault P, Perreault C, Pol J, Zitvogel L, Senovilla L, Kroemer G.

Immunol Rev. 2017 Nov;280(1):165-174. doi: 10.1111/imr.12582. Review.

PMID:
29027230
4.

Efficacy and Tolerability of IncobotulinumtoxinA for Treating Glabellar Frown Lines in Korean Adults: A Postmarketing Observational Study.

Park JY, Sung NK, Pitt JM.

Dermatol Surg. 2017 Sep 28. doi: 10.1097/DSS.0000000000001330. [Epub ahead of print]

PMID:
28961638
5.

Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Jacquelot N, Pitt JM, Enot DP, Roberti MP, Duong CPM, Rusakiewicz S, Eggermont AM, Zitvogel L.

Oncoimmunology. 2017 Mar 7;6(8):e1299303. doi: 10.1080/2162402X.2017.1299303. eCollection 2017. Review.

6.

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.

Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V, Préville X, Quéméneur E, Kepp O, Adam J, Marabelle A, Pitt JM, Kroemer G, Zitvogel L.

Cancer Res. 2017 Aug 1;77(15):4146-4157. doi: 10.1158/0008-5472.CAN-16-2165. Epub 2017 May 23.

7.

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L.

Oncoimmunology. 2016 Apr 25;6(1):e1137418. doi: 10.1080/2162402X.2015.1137418. eCollection 2017.

8.

Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota.

Pitt JM, Vétizou M, Gomperts Boneca I, Lepage P, Chamaillard M, Zitvogel L.

Oncoimmunology. 2016 Feb 18;6(1):e1132137. doi: 10.1080/2162402X.2015.1132137. eCollection 2017.

9.

Mouse models in oncoimmunology.

Zitvogel L, Pitt JM, Daillère R, Smyth MJ, Kroemer G.

Nat Rev Cancer. 2016 Dec;16(12):759-773. doi: 10.1038/nrc.2016.91. Epub 2016 Sep 30. Review.

PMID:
27687979
10.

Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome.

Pitt JM, Vétizou M, Waldschmitt N, Kroemer G, Chamaillard M, Boneca IG, Zitvogel L.

Cancer Res. 2016 Aug 15;76(16):4602-7. doi: 10.1158/0008-5472.CAN-16-0448. Epub 2016 Jul 29. Review.

11.

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.

Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L.

Immunity. 2016 Jun 21;44(6):1255-69. doi: 10.1016/j.immuni.2016.06.001. Review.

12.

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.

Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Théry C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vély F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N.

Oncoimmunology. 2015 Aug 12;5(4):e1071008. eCollection 2016 Apr.

13.

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.

Yamazaki T, Pitt JM, Vétizou M, Marabelle A, Flores C, Rekdal Ø, Kroemer G, Zitvogel L.

Cell Death Differ. 2016 Jun;23(6):1004-15. doi: 10.1038/cdd.2016.35. Epub 2016 Apr 15.

14.

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.

Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L.

Ann Oncol. 2016 Aug;27(8):1482-92. doi: 10.1093/annonc/mdw168. Epub 2016 Apr 10. Review.

PMID:
27069014
15.

Dendritic cell-derived exosomes for cancer therapy.

Pitt JM, André F, Amigorena S, Soria JC, Eggermont A, Kroemer G, Zitvogel L.

J Clin Invest. 2016 Apr 1;126(4):1224-32. doi: 10.1172/JCI81137. Epub 2016 Apr 1. Review.

16.

Extracellular vesicles: masters of intercellular communication and potential clinical interventions.

Pitt JM, Kroemer G, Zitvogel L.

J Clin Invest. 2016 Apr 1;126(4):1139-43. doi: 10.1172/JCI87316. Epub 2016 Apr 1. Review.

17.

Therapy-induced microenvironmental changes in cancer.

Ma Y, Yang H, Pitt JM, Kroemer G, Zitvogel L.

J Mol Med (Berl). 2016 May;94(5):497-508. doi: 10.1007/s00109-016-1401-8. Epub 2016 Mar 2. Review.

PMID:
26931513
18.

Analysis of Transcriptional Signatures in Response to Listeria monocytogenes Infection Reveals Temporal Changes That Result from Type I Interferon Signaling.

Pitt JM, Blankley S, Potempa K, Graham CM, Moreira-Teixeira L, McNab FW, Howes A, Stavropoulos E, Pascual V, Banchereau J, Chaussabel D, O'Garra A.

PLoS One. 2016 Feb 26;11(2):e0150251. doi: 10.1371/journal.pone.0150251. eCollection 2016.

19.

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, Yamazaki T, Roberti MP, Daillère R, Vétizou M, Poirier-Colame V, Semeraro M, Caignard A, Slingluff CL Jr, Sallusto F, Rusakiewicz S, Weide B, Marabelle A, Kohrt H, Dalle S, Cavalcanti A, Kroemer G, Di Giacomo AM, Maio M, Wong P, Yuan J, Wolchok J, Umansky V, Eggermont A, Zitvogel L.

J Clin Invest. 2016 Mar 1;126(3):921-37. doi: 10.1172/JCI80071. Epub 2016 Feb 8.

20.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L.

Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.

21.

Dendritic cell-derived exosomes as immunotherapies in the fight against cancer.

Pitt JM, Charrier M, Viaud S, André F, Besse B, Chaput N, Zitvogel L.

J Immunol. 2014 Aug 1;193(3):1006-11. doi: 10.4049/jimmunol.1400703. Review.

22.

Vaccination against tuberculosis: how can we better BCG?

Pitt JM, Blankley S, McShane H, O'Garra A.

Microb Pathog. 2013 May;58:2-16. doi: 10.1016/j.micpath.2012.12.002. Epub 2012 Dec 17. Review.

PMID:
23257069
23.

Blockade of IL-10 signaling during bacillus Calmette-Guérin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-γ and IL-17 responses and increases protection to Mycobacterium tuberculosis infection.

Pitt JM, Stavropoulos E, Redford PS, Beebe AM, Bancroft GJ, Young DB, O'Garra A.

J Immunol. 2012 Oct 15;189(8):4079-87. doi: 10.4049/jimmunol.1201061. Epub 2012 Sep 12.

24.

Supplemental Content

Support Center